{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:07:02Z","timestamp":1785002822463,"version":"3.55.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Fund for Regional Development","award":["PI15\/00285"],"award-info":[{"award-number":["PI15\/00285"]}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["14SGR1227"],"award-info":[{"award-number":["14SGR1227"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.metabol.2016.01.002","type":"journal-article","created":{"date-parts":[[2016,1,11]],"date-time":"2016-01-11T00:45:14Z","timestamp":1452473114000},"page":"609-622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status"],"prefix":"10.1016","volume":"65","author":[{"given":"Amirhossein","family":"Sahebkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hern\u00e1ndez-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Abell\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Joven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2016.01.002_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2012.03.127","article-title":"How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol","volume":"166","author":"Lim","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0010","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2016.01.002_bb0015","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11154-014-9298-4","article-title":"Pharmacological treatment and therapeutic perspectives of metabolic syndrome","volume":"15","author":"Lim","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.metabol.2016.01.002_bb0020","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archinte.1981.00340090024008","article-title":"Lipoproteins, cardiovascular disease, and death. The Framingham study","volume":"141","author":"Gordon","year":"1981","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"10.1016\/j.metabol.2016.01.002_bb0030","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0035","doi-asserted-by":"crossref","DOI":"10.1186\/1742-6405-6-26","article-title":"Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes","volume":"6","author":"Alonso-Villaverde","year":"2009","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.metabol.2016.01.002_bb0040","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2174\/138955709788681591","article-title":"Pharmacological and lifestyle factors modulating serum paraoxonase-1 activity","volume":"9","author":"Camps","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.metabol.2016.01.002_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejphar.2006.06.014","article-title":"Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy","volume":"544","author":"Coll","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0050","doi-asserted-by":"crossref","first-page":"20997","DOI":"10.3390\/ijms151120997","article-title":"Exploring the role of paraoxonases in the pathogenesis of coronary artery disease: a systematic review","volume":"15","author":"Abell\u00f3","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2016.01.002_bb0055","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40265-013-0072-9","article-title":"A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs","volume":"73","author":"Alla","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2016.01.002_bb0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.metabol.2013.10.013","article-title":"Glycation of human high density lipoprotein by methylglyoxal: effect on HDL-paraoxonase activity","volume":"63","author":"Bacchetti","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2016.01.002_bb0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00032-X","article-title":"Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation","volume":"138","author":"Aviram","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0070","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/biof.1021","article-title":"VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies","volume":"38","author":"Rosenblat","year":"2012","journal-title":"Biofactors"},{"key":"10.1016\/j.metabol.2016.01.002_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/156053","article-title":"Paraoxonase-1 inhibits oxidized low-density lipoprotein-induced metabolic alterations and apoptosis in endothelial cells: a nondirected metabolomic study","author":"Garc\u00eda-Heredia","year":"2013","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.metabol.2016.01.002_bb0080","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2016.01.002_bb0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s11886-002-0113-6","article-title":"Dyslipidemia of the metabolic syndrome","volume":"4","author":"Ruotolo","year":"2002","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.metabol.2016.01.002_bb0090","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nature05487","article-title":"Mechanisms linking obesity with cardiovascular disease","volume":"444","author":"Van Gaal","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2016.01.002_bb0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1179\/1351000214Y.0000000103","article-title":"Paraoxonase responses to exercise and niacin therapy in men with metabolic syndrome","volume":"20","author":"Taylor","year":"2015","journal-title":"Redox Rep"},{"key":"10.1016\/j.metabol.2016.01.002_bb0100","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1373\/49.9.1491","article-title":"Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population","volume":"49","author":"Ferr\u00e9","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.metabol.2016.01.002_bb0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/156652411796268713","article-title":"The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease","volume":"11","author":"Rull","year":"2011","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tox.2012.07.011","article-title":"Paraoxonase 1 (PON1) as a genetic determinant of susceptibility to organophosphate toxicity","volume":"307","author":"Costa","year":"2013","journal-title":"Toxicology"},{"key":"10.1016\/j.metabol.2016.01.002_bb0115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.freeradbiomed.2008.03.023","article-title":"Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues","volume":"45","author":"Marsillach","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0120","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/iub.347","article-title":"Human tissue distribution of paraoxonases 1 and 2 mRNA","volume":"62","author":"Mackness","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.metabol.2016.01.002_bb0125","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1021\/bi047440d","article-title":"Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase","volume":"44","author":"Khersonsky","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.metabol.2016.01.002_bb0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/cbic.200500334","article-title":"Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases","volume":"7","author":"Khersonsky","year":"2006","journal-title":"Chembiochem"},{"key":"10.1016\/j.metabol.2016.01.002_bb0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10408360802610878","article-title":"The paraoxonases: role in human diseases and methodological difficulties in measurement","volume":"46","author":"Camps","year":"2009","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.metabol.2016.01.002_bb0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/iub.588","article-title":"Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation","volume":"64","author":"Hine","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.metabol.2016.01.002_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/616371","article-title":"PPARs in regulation of paraoxonases: control of oxidative stress and inflammation pathways","author":"Camps","year":"2012","journal-title":"PPAR Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0150","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/1535370214535897","article-title":"Paraoxonases function as unique protectors against cardiovascular diseases and diabetes: updated experimental and clinical data","volume":"239","author":"Li","year":"2014","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-405211-6.00003-6","article-title":"Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease","volume":"59","author":"Martinelli","year":"2013","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.metabol.2016.01.002_bb0160","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/B978-0-12-800094-6.00007-8","article-title":"Paraoxonases and chemokine (C-C motif) ligand-2 in noncommunicable diseases","volume":"63","author":"Camps","year":"2014","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.metabol.2016.01.002_bb0165","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2016.01.002_bb0170","first-page":"421","article-title":"Brimful of STARLITE: toward standards for reporting literature searches","volume":"94","author":"Booth","year":"2006","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.metabol.2016.01.002_bb0175","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-9150(98)00003-3","article-title":"Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia","volume":"138","author":"Durrington","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0180","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.metabol.2016.01.002_bb0185","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/sim.1040","article-title":"Advanced methods in meta-analysis: multivariate approach and meta-regression","volume":"21","author":"van Houwelingen","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0190","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/bmj.315.7121.1533","article-title":"Meta-analysis: principles and procedures","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.metabol.2016.01.002_bb0195","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","article-title":"Meta-analysis and subgroups","volume":"14","author":"Borenstein","year":"2013","journal-title":"Prev Sci"},{"key":"10.1016\/j.metabol.2016.01.002_bb0205","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/sim.6115","article-title":"Statistics for quantifying heterogeneity in univariate and bivariate meta-analyses of binary data: the case of meta-analyses of diagnostic accuracy","volume":"33","author":"Zhou","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0210","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.phrs.2015.10.013","article-title":"Statin therapy and plasma cortisol concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"103","author":"Sahebkar","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.phrs.2015.09.012","article-title":"Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"102","author":"Derosa","year":"2015","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0220","series-title":"Cochrane handbook for systematic reviews of interventions. Version 5.0.2","year":"2009"},{"key":"10.1016\/j.metabol.2016.01.002_bb0225","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1517\/14656566.2011.591383","article-title":"The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia","volume":"12","author":"Agouridis","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.metabol.2016.01.002_bb0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2362.2009.02090.x","article-title":"Serum paraoxonase-1 activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus","volume":"39","author":"Dullaart","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2016.01.002_bb0235","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2007.03.001","article-title":"Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels","volume":"196","author":"Phuntuwate","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0240","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1365-2125.2006.02565.x","article-title":"Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome","volume":"61","author":"Paragh","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0245","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1194\/jlr.M200452-JLR200","article-title":"Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins","volume":"44","author":"Tsimihodimos","year":"2003","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1262-3636(07)70077-0","article-title":"The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease","volume":"29","author":"Paragh","year":"2003","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2016.01.002_bb0255","first-page":"604","article-title":"Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?","volume":"27","author":"Balogh","year":"2001","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metabol.2016.01.002_bb0260","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00044011-200019040-00005","article-title":"Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia","volume":"19","author":"Paragh","year":"2000","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.metabol.2016.01.002_bb0265","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/sim.698","article-title":"A comparison of methods to detect publication bias in meta-analysis","volume":"20","author":"Macaskill","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0270","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.metabol.2016.01.002_bb0275","first-page":"464","article-title":"The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis","volume":"59","author":"Rosenberg","year":"2005","journal-title":"Evolution"},{"key":"10.1016\/j.metabol.2016.01.002_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2015.08.003","article-title":"Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials","author":"Ferretti","year":"2015","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0285","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.110.960112","article-title":"Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"122","author":"Tonkin","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2016.01.002_bb0290","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2016.01.002_bb0295","first-page":"598","article-title":"Molecular basis for the polymorphic forms of human serum paraoxonase\/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes","volume":"52","author":"Adkins","year":"1993","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.metabol.2016.01.002_bb0300","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(04)15642-0","article-title":"Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies","volume":"363","author":"Wheeler","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2016.01.002_bb0305","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1161\/01.ATV.20.11.2441","article-title":"Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype","volume":"20","author":"Jarvik","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0310","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/mol.63.4.945","article-title":"Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins","volume":"63","author":"Gou\u00e9dard","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0315","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1365-2796.2005.01557.x","article-title":"The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia","volume":"258","author":"Himbergen","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0320","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1194\/jlr.D014134","article-title":"Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study","volume":"52","author":"Aragon\u00e8s","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0325","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/nm.2386","article-title":"Paraoxonase-1 and clopidogrel efficacy","volume":"17","author":"Camps","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0330","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","article-title":"Recent advances in pharmacotherapy for hypertriglyceridemia","volume":"56","author":"Sahebkar","year":"2014","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0335","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.atherosclerosis.2015.03.016","article-title":"Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: a systematic review and meta-analysis of randomized controlled trials","volume":"240","author":"Sahebkar","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0340","doi-asserted-by":"crossref","first-page":"17527","DOI":"10.1074\/jbc.M910376199","article-title":"Combined serum paraoxonase knockout\/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis","volume":"275","author":"Shih","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2016.01.002_bb0345","doi-asserted-by":"crossref","first-page":"29491","DOI":"10.1074\/jbc.M605379200","article-title":"Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2","volume":"281","author":"Ng","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2016.01.002_bb0350","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1096\/fj.14-260570","article-title":"PON3 knockout mice are susceptible to obesity, gallstone formation, and atherosclerosis","volume":"29","author":"Shih","year":"2015","journal-title":"FASEB J"},{"key":"10.1016\/j.metabol.2016.01.002_bb0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosis.2004.12.030","article-title":"Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice","volume":"181","author":"Rozenberg","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0360","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/ATVBAHA.106.134189","article-title":"Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice","volume":"27","author":"Ng","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0365","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijcard.2009.03.035","article-title":"The importance of considering alternative or combination strategies for lowering LDL-C","volume":"136","author":"Koh","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0370","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.metabol.2016.01.002_bb0375","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0021-9150(03)00006-6","article-title":"High density lipoproteins (HDLs) and atherosclerosis: the unanswered questions","volume":"168","author":"Barter","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0380","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1311039","article-title":"Safety profile of extended-release niacin in the AIM-HIGH trial","volume":"371","author":"Anderson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0385","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.numecd.2014.09.003","article-title":"Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials","volume":"25","author":"Verdoia","year":"2015","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0395","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/HCO.0b013e328362059d","article-title":"Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol","volume":"28","author":"Wright","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0400","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/VHRM.S25238","article-title":"Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases","volume":"8","author":"Shinkai","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2016.01.002_bb0405","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1464-5491.2002.00660.x","article-title":"Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes","volume":"19","author":"Kao","year":"2002","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0410","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.2337\/db13-0800","article-title":"An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes","volume":"62","author":"Noonan","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2016.01.002_bb0415","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejim.2011.12.007","article-title":"Fibrates: therapeutic potential for diabetic nephropathy?","volume":"23","author":"Kouroumichakis","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.metabol.2016.01.002_bb0420","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1475-2840-12-82","article-title":"Selective peroxisome proliferator-activated receptor \u03b1 modulators (SPPARM\u03b1): the next generation of peroxisome proliferator-activated receptor \u03b1-agonists","volume":"12","author":"Fruchart","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0425","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656566.2014.876992","article-title":"New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease","volume":"15","author":"Sahebkar","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.metabol.2016.01.002_bb0430","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1021\/bi8014746","article-title":"Correlation of structural stability with functional remodeling of high-density lipoproteins: the importance of being disordered","volume":"47","author":"Guha","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.metabol.2016.01.002_bb0435","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10620-007-9911-4","article-title":"Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver","volume":"53","author":"Ackerman","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.metabol.2016.01.002_bb0440","doi-asserted-by":"crossref","first-page":"321","DOI":"10.18388\/abp.2010_2411","article-title":"Effects of high sucrose diet, gemfibrozil, and their combination on plasma paraoxonase 1 activity and lipid levels in rats","volume":"57","author":"Macan","year":"2010","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0445","first-page":"463","article-title":"The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity","volume":"53","author":"Be\u0142towski","year":"2002","journal-title":"J Physiol Pharmacol"},{"issue":"4","key":"10.1016\/j.metabol.2016.01.002_bb0450","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.metabol.2013.12.009","article-title":"Increased expression of oxidative enzymes in adipose tissue following PPAR\u03b1-activation","volume":"63","author":"Ferreira","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2016.01.002_bb0455","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1021\/pr400050u","article-title":"Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach","volume":"12","author":"Garc\u00eda-Heredia","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0460","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-07320-0_5","article-title":"Inflammation, infection, cancer and all that\u2026the role of paraoxonases","volume":"824","author":"Devarajan","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0465","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1021\/pr401230s","article-title":"Rosiglitazone and fenofibrate exacerbate liver steatosis in a mouse model of obesity and hyperlipidemia. A transcriptomic and metabolomic study","volume":"13","author":"Rull","year":"2014","journal-title":"J Proteome Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0470","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrcardio.2010.222","article-title":"HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms","volume":"8","author":"Navab","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0475","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/VHRM.S37119","article-title":"Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes","volume":"9","author":"Kones","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.metabol.2016.01.002_bb0480","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2016.01.002_bb0485","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbalip.2013.10.012","article-title":"Searching for a successful HDL-based treatment strategy","volume":"184","author":"Reddy","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2016.01.002_bb0490","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/cc.28079","article-title":"Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites","volume":"13","author":"Menendez","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.metabol.2016.01.002_bb0495","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.amjcard.2006.04.033","article-title":"Comparison of mortality rates in statin users versus nonstatin users in a United States veteran population","volume":"98","author":"Mehta","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0500","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.exger.2013.02.020","article-title":"Aspirin extends the lifespan of Caenorhabditis elegans via AMPK and DAF-16\/FOXO in dietary restriction pathway","volume":"48","author":"Wan","year":"2013","journal-title":"Exp Gerontol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0505","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.96.9.3164","article-title":"Long-term ACE inhibition doubles lifespan of hypertensive rats","volume":"96","author":"Linz","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2016.01.002_bb0510","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1476-511X-12-54","article-title":"Effect of insulin analog initiation therapy on LDL\/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients","volume":"12","author":"Aslan","year":"2013","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.metabol.2016.01.002_bb0515","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.thromres.2013.12.034","article-title":"Role of paraoxonase-1 in CYP2C19 loss-of-function carriers","volume":"133","author":"Daali","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.metabol.2016.01.002_bb0520","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/nrendo.2014.159","article-title":"Dyslipidaemia: cardiovascular prevention\u2014end of the road for niacin?","volume":"10","author":"Tuteja","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2016.01.002_bb0525","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1185\/03007990802363198","article-title":"Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey","volume":"24","author":"Zhang","year":"2008","journal-title":"Curr Med Res Opin"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049516000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049516000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:10:04Z","timestamp":1758427804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049516000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0026049516000056"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2016.01.002","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2016.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}